Bold take: Soroka’s value at $7.5 million isn’t just about today’s innings—it’s about the upside of a potential league-average starter at a fraction of the cost. But here’s where it gets controversial: does setting up a reliable, swingman role equal smart risk, or is there a hidden cost in long-term development and health? Let’s unpack what happened and what it could mean for a team like the Diamondbacks.
Michael Soroka remains a player with clear flashes of potential. Last season represented his second-best effort, earning 1.1 fWAR across a combined workload for the Nationals and Cubs. In 2016, he delivered 1.2 fWAR over 16 starts for the Nationals, but his performance tailed off dramatically as he barely pitched for the Cubs down the stretch. If you’re evaluating his trajectory, the data suggests a pitcher who can be effective in bursts but has faced durability questions in recent years.
Looking ahead, Soroka’s expected role projects around league-average quality of innings, with a heavier emphasis on a swingman workload. His xFIP in 2025 mirrored his FIP, implying limited upside tied to HR/FB suppression. However, his contact management showed a meaningful improvement relative to his peripherals and the number of runs allowed, hinting that there could be continued gains if he can fine-tune sequencing and command. The standout element of his repertoire is the slider-like breaking ball, often described as a “slurve.” It’s the pitch that plays well off his other offerings, which mostly function as setup tools. Notably, he did throw a slider previously, but the slurve sits roughly two miles per hour slower, which can affect swing-and-miss rates and bat-to-ball timing.
The Diamondbacks acted quickly, signing Soroka for $7.5 million. From their perspective, this move makes sense: their rotation isn’t projected to be among the league’s strongest, so upgrading with a cost-controlled arm who could become a league-average starter for a modest price is appealing. The downside risk is low—at worst, he’s a dependable long reliever—while the upside could yield a productive starter for far less than the market price of a true front-line arm.
If you’re evaluating the decision in a vacuum, it’s a straightforward call I would likely endorse. It’s not just about affection for Soroka; it’s about balancing cost, upside, and depth. The Braves’ hesitation, if any, might stem from concerns about Truist Park’s mound or other strategic plans for the rotation. Other teams could have different risk tolerances or development timelines influencing their verdicts.
Would you have pursued this signing, considering the full package—consistency, durability, and the potential return on a relatively low-cost investment? Or would you push for a different allocation of resources, prioritizing higher upside at the risk of greater volatility? Share your take and tell me where you stand on paying for potential versus certainty in this kind of signing.
